ACL Managements' misfire on Friday (last minute meeting cancellation) doesn't appear to have dampened the demand for the stock in anticipation of an approved split of the company's oncology asset (HA-Irinotecan) for a NASDAQ listing.
Up 3.64% in this morning's trade.
